mRNA-seq with agnostic splice site discovery for nervous system transcriptomics tested in chronic pain.
mRNA-seq is a paradigm-shifting technology because of its superior sensitivity and dynamic range and its potential to capture transcriptomes in an agnostic fashion, i.e., independently of existing genome annotations. Implementation of the agnostic approach, however, has not yet been fully achieved. In particular, agnostic mapping of pre-mRNA splice sites has not been demonstrated. The present study pursued dual goals: (1) to advance mRNA-seq bioinformatics toward unbiased transcriptome capture and (2) to demonstrate its potential for discovery in neuroscience by applying the approach to an in vivo model of neurological disease. We have performed mRNA-seq on the L4 dorsal root ganglion (DRG) of rats with chronic neuropathic pain induced by spinal nerve ligation (SNL) of the neighboring (L5) spinal nerve. We found that 12.4% of known genes were induced and 7% were suppressed in the dysfunctional (but anatomically intact) L4 DRG 2 wk after SNL. These alterations persisted chronically (2 mo). Using a read cluster classifier with strong test characteristics (ROC area 97%), we discovered 10,464 novel exons. A new algorithm for agnostic mapping of pre-mRNA splice junctions (SJs) achieved a precision of 97%. Integration of information from all mRNA-seq read classes including SJs led to genome reannotations specifically relevant for the species used (rat), the anatomical site studied (DRG), and the neurological disease considered (pain); for example, a 64-exon coreceptor for the nociceptive transmitter substance P was identified, and 21.9% of newly discovered exons were shown to be dysregulated. Thus, mRNA-seq with agnostic analysis methods appears to provide a highly productive approach for in vivo transcriptomics in the nervous system.
Hammer
Paul
P
University of Applied Sciences, Wildau 15745, Germany.
Banck
Michaela S
MS
Amberg
Ronny
R
Wang
Cheng
C
Petznick
Gabriele
G
Luo
Shujun
S
Khrebtukova
Irina
I
Schroth
Gary P
GP
Beyerlein
Peter
P
Beutler
Andreas S
AS
D000818:Animals; D002908:Chronic Disease; D005727:Ganglia, Spinal / Q000378:metabolism*; D020869:Gene Expression Profiling; D010146:Pain / Q000235:genetics*; D012326:RNA Splicing; D012333:RNA, Messenger / Q000235:genetics*; D051381:Rats
D012333:RNA, Messenger
Nat Genet. 2008 Dec;40(12):1413-5
18978789
Science. 2005 Sep 2;309(5740):1564-6
16141073
Nature. 2008 Jun 26;453(7199):1239-43
18488015
Nat Methods. 2008 Jan;5(1):19-21
18165803
Trends Genet. 2005 Feb;21(2):93-102
15661355
Nature. 2008 Nov 27;456(7221):470-6
18978772
Genome Res. 2008 Sep;18(9):1509-17
18550803
Nature. 2008 Nov 6;456(7218):53-9
18987734
Genome Biol. 2003;4(2):105
12620110
Nat Methods. 2008 Jul;5(7):621-8
18516045
J Neurochem. 2003 Nov;87(3):560-73
14535940
BMC Neurosci. 2002 Aug 20;3:11
12188929
Science. 2008 Aug 15;321(5891):956-60
18599741
Genome Biol. 2009;10(3):R25
19261174
Nature. 2007 Jun 14;447(7146):799-816
17571346
J Neurosci. 2002 Feb 15;22(4):1303-15
11850458
Methods Mol Med. 2004;99:35-45
15131327
BMC Neurosci. 2002 Oct 25;3:16
12401135
Nature. 2009 Feb 5;457(7230):741-4
19092807
Nat Methods. 2008 Jul;5(7):613-9
18516046
Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):1055-60
18215993
Science. 2008 Jun 6;320(5881):1344-9
18451266
Nat Rev Genet. 2009 Jan;10(1):57-63
19015660
Bioinformatics. 2009 May 1;25(9):1105-11
19289445
Curr Opin Mol Ther. 2005 Oct;7(5):431-9
16248278
Genome Res. 2010 Jan;20(1):45-58
19858364
PLoS One. 2008;3(11):e3625
18985160
Science. 2007 Jun 8;316(5830):1497-502
17540862
Genome Res. 2009 Jun;19(6):1044-56
19273619
Nat Biotechnol. 2006 Sep;24(9):1151-61
16964229
Nat Med. 2006 Nov;12(11):1269-77
17057711
J Physiol Pharmacol. 2006 Sep;57(3):401-14
17033093